X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

U.S. FDA Approves DARZALEX Split-Dosing Regimen

Content Team by Content Team
13th February 2019
in FDA Approvals, Press Statements
U.S. FDA Approves DARZALEX Split-Dosing Regimen

The U.S. FDA gave Janssen Biotech, a Johnson & Johnson company, and their research partner, Copenhagen, Denmark-based Genmab A/S, an approval for their Darzalex split-dosing regimen.

Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant. It is also approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for MM who have had at least one previous therapy; and in combination with pomalidomide and dexamethasone for patients with MM who’ve had at least two previous treatments, including lenalidomide and a proteasome inhibitor.

It has also been approved as a monotherapy for patients with MM who have received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, who are double-refractory to a proteasome inhibitor and an immunomodulatory therapy.

The FDA’s approval for the supplemental Biologics License Application (sBLA), which was submitted by Janssen in July 2018, was supported by data from the EQUULEUS (MMY1001) Phase Ib open-label trial. This study included up to 240 patients and evaluated the safety, tolerability and dose of the drug when administered in combination with various “backbone treatment regimens for different settings of multiple myeloma.”

The split infusion provides the drug over two consecutive days. That dosing regimen was approved in December 2018 by the European Commission.

“We are pleased that, with this change, patients in the U.S. receiving their first infusion of Darzalex may now have this more flexible dosing options,” stated Jan van de Winkel, Genmab’s chief executive officer.

On Feb. 5, Paris-based Sanofi announced positive data from its Phase III trial of isatuximab in patients with r/r multiple myeloma, which could be a competitor to Darzalex. The company plans to present the data at a medical meeting and be the basis for regulatory submissions later this year.

Multiple myeloma is the second most common hematologic cancer. About 138,000 new cases are diagnosed globally each year. For most patients, it is largely incurable.

The trial, ICARIA-MM, enrolled 307 patients with r/r MM across 96 sites in 24 countries. All participants received two or more previous anti-myeloma therapies, including at least two consecutive cycles of lenalidomide and a proteasome inhibitor alone or in combination. Isatuximab was administered via an IV infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with regular doses of pomalidomide and dexamethasone.

Like Darzalex, isatuximab targets a specific epitope of CD38 that can trigger multiple mechanisms of action to promote cell death and immunomodulatory activity.

“We are excited by these results, which represent significant progress in our ambition to extend the lives of multiple myeloma patients,” stated John Reed, Head of Research and Development at Sanofi. “We look forward to engaging with regulatory authorities with the goal of bringing this potential new treatment to patients as quickly as possible.”

There wasn’t enough data in Sanofi’s release to indicate whether isatuximab will be a real competitor to Darzalex. Isatuximab is also being studied in three other Phase III trials in slightly different patient populations or in combination with other standard-of-care therapies.

 

Previous Post

EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

Next Post

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

Related Posts

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
FDA Approvals

WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

21st February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Next Post
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In